Editas Medicine, Inc. (LON:0IFK)

Market Cap	126.64M +34.4%
Revenue (ttm)	34.51M -24.9%
Net Income	-148.67M
EPS	-1.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,436
Average Volume	12,566
Open	1.800
Previous Close	1.740
Day's Range	1.700 - 1.800
52-Week Range	0.920 - 4.530
Beta	2.16
RSI	35.38
Earnings Date	Mar 5, 2026

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2013
• Employees: 246
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IFK

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Financial numbers in USD